eVetPractice vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud veterinary practice management covering records, scheduling, invoicing, and pharmacy for small-animal clinics. El Segundo CA; developed by Covetrus as the cloud-native complement to legacy AVImark;
About
eVetPractice is an El Segundo, California-based cloud-based veterinary practice management software that provides independent veterinary clinics with scheduling, electronic medical records, treatment tracking, invoicing, pharmacy management, and client communication in a single web-based platform. Developed by Covetrus, eVetPractice represents the company's cloud-native veterinary practice management offering alongside its legacy AVImark on-premise system, targeting practices ready to move to a browser-based system without the hardware and IT maintenance overhead of on-premise software. The platform is designed for small-animal general practices and emergency hospitals, with clinical templates and workflows appropriate for companion animal medicine.\n\neVetPractice's pharmacy management module is a notable capability, allowing veterinary practices to manage in-clinic medication dispensing, track controlled substance logs, and connect to online pharmacy fulfillment through Covetrus's online pharmacy network. This pharmaceutical connectivity aligns with Covetrus's broader strategy of integrating its animal health distribution and pharmacy businesses with its practice management software. Practices using eVetPractice can process prescription refill requests and manage client prescription histories within the same system used for scheduling and medical records, reducing the context-switching that comes with managing separate pharmacy and practice management platforms.\n\neVetPractice competes with Shepherd, Digitail, ezyVet, and the modernized versions of legacy systems in the cloud veterinary practice management market. The company's positioning within Covetrus gives it integration advantages with the broader Covetrus ecosystem including diagnostic imaging, laboratory connectivity, and prescription management, but also means its development roadmap is influenced by the priorities of a large animal health distributor rather than solely by independent veterinary practice needs. eVetPractice serves practices primarily in the United States with a focus on the independent practice segment.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.